10-Q: Stereotaxis Q3: Revenue Dip, New Product Approvals, Capital Boost

Stereotaxis reports a 19% revenue decrease in Q3 2025, but a 15% increase year-to-date, driven by disposables, alongside key regulatory approvals and a $7.8 million equity raise.

Summary

• Total revenue for the three months ended September 30, 2025, decreased by 19% to $7.5 million from $9.2 million in the prior year period.
• Year-to-date revenue for the nine months ended September 30, 2025, increased by 15% to $23.7 million from $20.6 million in the prior year period.
• Systems revenue for Q3 2025 decreased to $1.9 million from $4.4 million in Q3 2024, while disposables, service, and accessories revenue increased by 17% to $5.6 million.
• Year-to-date systems revenue decreased to $6.9 million from $7.2 million, but disposables, service, and accessories revenue increased by 27% to $16.9 million.
• Gross margin for Q3 2025 improved to 55% from 45% in Q3 2024, primarily due to changes in product mix.
• Operating loss for Q3 2025 increased to $(6.6) million from $(6.3) million in Q3 2024.
• Net loss attributable to common stockholders for Q3 2025 was $(6.8) million, compared to $(6.5) million in Q3 2024.
• Year-to-date net loss attributable to common stockholders improved to $(17.1) million from $(17.5) million in the prior year period.
• Cash and cash equivalents stood at $10.5 million as of September 30, 2025, down from $12.2 million at December 31, 2024.
• The company completed a registered direct offering on July 17, 2025, raising $7.8 million in net proceeds and agreed to sell an additional $4.0 million in shares by November 25, 2025.
• An At-The-Market (ATM) Program for up to $50.0 million of common stock was established on August 29, 2025, with no shares issued as of September 30, 2025.
• Key product regulatory approvals include FDA 510(k) clearance for GenesisX RMN System (Q4 2025) and MAGiC Sweep catheter (July 2025), and CE Mark for Synchrony system (Oct 2025) and Stereotaxis MAGiC catheter (Q1 2025).

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While Q3 revenue declined and losses persist, the year-to-date revenue growth, significant new product regulatory approvals, and successful capital raises provide a positive outlook for future growth and liquidity. However, substantial macroeconomic risks and the ongoing need for funding temper enthusiasm.

Positives

• Year-to-date total revenue increased by 15% to $23.7 million, driven by strong growth in disposables, service, and accessories revenue (up 27% year-to-date).
• Gross margin percentage for the three months ended September 30, 2025, increased significantly to 55% from 45% in the prior year, indicating improved product mix efficiency.
• The company secured significant regulatory clearances for new products, including FDA 510(k) for the GenesisX RMN System (Q4 2025) and MAGiC Sweep catheter (July 2025), and CE Mark for the Synchrony system (Oct 2025) and Stereotaxis MAGiC catheter (Q1 2025), expanding market access and product portfolio.
• Successful completion of a registered direct offering in July 2025 raised $7.8 million in net proceeds, enhancing liquidity.
• An agreement to sell an additional $4.0 million in shares by November 25, 2025, further strengthens capital resources.
• Establishment of an ATM Program for up to $50.0 million provides future capital raising flexibility.
• The acquisition of Access Point Technologies EP, Inc. (APT) in July 2024 provides in-house catheter development and manufacturing expertise, supporting innovation efforts.

Negatives

• Total revenue for the three months ended September 30, 2025, decreased by 19% compared to the same period in the prior year, primarily due to decreased system sales volume.
• System sales revenue decreased both for the three-month period (down from $4.4 million to $1.9 million) and the nine-month period (down from $7.2 million to $6.9 million).
• The company continues to incur significant net losses, with a cumulative net loss of approximately $577.8 million as of September 30, 2025, and expects additional losses in 2025.
• Cash and cash equivalents decreased to $10.5 million at September 30, 2025, from $12.2 million at December 31, 2024.
• General and administrative expenses increased by 7% for the three-month period and 13% for the nine-month period, partly driven by the revaluation of contingent consideration from the APT acquisition.
• Interest income decreased for both the three-month and nine-month periods due to lower invested balances and interest rates.

Risks

• The global tariff environment, particularly U.S.-China tariffs and proposed increases, could materially affect cost structure, gross margins, and product launch timing.
• Macroeconomic and geopolitical factors, including inflationary pressures, elevated interest rates, supply chain challenges, and international conflicts, could adversely impact operations and liquidity.
• Periodic worldwide supply chain disruptions, including shortages, inflationary pressures, tariffs, and logistics delays, make it difficult to source parts and ship products, potentially interrupting manufacturing or service.
• Hospital customers face staffing and cost pressures, liquidity concerns from elevated interest rates, and challenges in sourcing supplies, which could cause delays or cancellations of purchase orders, longer sales cycles, and decreased demand for disposable products.
• Disruptions to capital markets could negatively impact the company's ability to raise capital on acceptable terms, or at all, potentially leading to delays in product development or commercialization, or even cessation of operations.
• Occurrences similar to the COVID-19 pandemic could negatively affect demand for systems and disposable products, leading to business disruptions and reduced procedure volumes.
• Managing APT's catheter manufacturing business is complex and highly technical, with dated prior experience, and is subject to supply chain disruptions, labor shortages, and potentially higher overhead.
• The company relies on strategic relationships with fluoroscopy system manufacturers and providers of catheters and mapping systems, and there are no guarantees these relationships will continue or that equivalent alternatives can be obtained on competitive terms.

Future Outlook

The company plans to advance the adoption of its robotic magnetic navigation systems and proprietary devices in markets with regulatory clearance and pursue approvals in pending geographies, aiming to further clinical adoption and new system placements. It expects to incur additional losses in 2025 due to continued product development, commercialization, R&D activities, and sales and marketing initiatives. The company will monitor the macroeconomic environment's impact on project timing, regulatory approvals, and customer/supplier operations. It anticipates funding operations primarily through past and future public offerings and private sales of equity securities, believing existing cash and proceeds from the July 2025 equity raise will be sufficient, but cannot guarantee additional funding won't be needed or available on acceptable terms.

Management Comments

• We believe the benefits of Robotic Magnetic Navigation can be applicable in other endovascular indications where navigation through complex vasculature is often challenging or unsuccessful and generates significant x-ray exposure, and we are investing in research and development in these areas.
• The integration with APT provides in-house catheter development, manufacturing expertise and specialized knowledge that will further Stereotaxis innovation efforts in developing a broad family of interventional devices navigated by our robots within electrophysiology and across a range of endovascular procedures.
• We expect to incur additional losses in 2025 as we continue the development and commercialization of our products, conduct our research and development activities, advance new products into clinical development from our existing research programs and fund additional sales and marketing initiatives.
• While we believe our existing cash and cash equivalents, including the proceeds from our July 2025 equity raise, will be sufficient to fund our operating expenses and capital equipment requirements, in light of the macroeconomic environment, we cannot guarantee that we will not need additional funding in the future.

Industry Context

The company operates in the cardiac ablation market, a multi-billion-dollar medical device market with expectations for substantial long-term growth. Its Robotic Magnetic Navigation technology aims to improve precision, stability, reach, and safety in endovascular interventions, with a primary focus on electrophysiology. The expansion into in-house catheter development through the APT acquisition and the pursuit of regulatory approvals for new systems and catheters (e.g., GenesisX, Synchrony, MAGiC) positions the company to capitalize on market growth and address unmet needs in complex procedures. The shift towards eliminating lengthy installation cycles for new RMN systems (GenesisX) and digitizing cath labs (Synchrony, SynX) aligns with broader industry trends for efficiency and accessibility in medical technology. However, the industry is also subject to macroeconomic pressures, supply chain disruptions, and hospital financial constraints, which can impact capital purchases and procedure volumes.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• A vendor filed financing statements under the Uniform Commercial Code (UCC) on underlying inventory for approximately $0.6 million in February 2024, which the company is fully contesting.

Stakeholder Impact

• Shareholders: Dilution from recent and planned equity raises, but improved liquidity and potential for future growth from new product approvals and market expansion.
• Customers (Hospitals): Benefit from new, more accessible robotic systems (GenesisX) and enhanced lab solutions (Synchrony, SynX), but face potential delays in system installations and supply shortages due to macroeconomic pressures.
• Employees: Continued investment in R&D and commercialization suggests ongoing opportunities, but the company's ongoing losses and need for capital raises indicate financial sensitivity.
• Suppliers: Subject to global supply chain disruptions, inflationary pressures, and tariffs, which could impact their ability to provide parts and services to the company.
• Creditors: No debt reported, but the company's reliance on equity financing and ongoing losses indicate a need for careful monitoring of financial health.

Next Steps

• Advance adoption of robotic magnetic navigation systems and proprietary devices in markets where regulatory clearance has been received.
• Work with regulatory approval authorities in geographies where approval is pending to further clinical adoption and new system placements.
• Continue development and commercialization of products, conduct research and development activities, and advance new products into clinical development.
• Fund additional sales and marketing initiatives.
• Monitor the impact of the macroeconomic environment on project timing, regulatory approvals, customer and supplier operations, and operating results.
• Explore financing alternatives to ensure adequate funds are available for operations and growth.
• Integrate APT's business and implement safeguards to minimize negative impacts on financial position, results of operations, and cash flows post-acquisition.

Key Dates

Recommendation

The company presents a mixed financial picture with a Q3 revenue decline but strong year-to-date growth driven by disposables. Significant regulatory approvals for new, innovative products like GenesisX RMN and MAGiC Sweep catheter are strong positive catalysts for future growth and market penetration. The recent capital raises provide essential liquidity for ongoing operations and product commercialization. However, the company continues to incur substantial net losses and relies heavily on equity financing, which dilutes existing shareholders. Furthermore, it faces considerable macroeconomic headwinds, including tariffs, supply chain disruptions, and hospital financial pressures, which could impact future performance. A 'hold' recommendation is appropriate as the long-term potential from its technology and product pipeline is promising, but current financial performance and external risks warrant a cautious approach, requiring investors to monitor execution and market adoption closely.

Keywords

Robotic Magnetic Navigation, Cardiac Ablation, Electrophysiology, Medical Devices, SEC Filing, Q3 Earnings, Revenue, Net Loss, Capital Raise, FDA Clearance, CE Mark, Catheter, Synchrony, SynX, GenesisX RMN, MAGiC Catheter, MAGiC Sweep, APT Acquisition, Tariffs, Supply Chain